JCCG神経芽腫委員会(JNBSG)業績

平成23年（2011年）〜令和5年（2023年）

 ［Ⅱ］総説・原著

A）英文
    • Tonini GP, Nakagawara A, Berthold F: Towards a turning point of neuroblastoma therapy. Cancer Lett, 326: 128-134, 2012.
  2. Fumino S, Kimura K, Iehara T, Nishimura M, Nakamura S, Souzaki R, Nishie A, Taguchi T, Hosoi H, Tajiri T: Validity of image-defined risk factors in localized neuroblastoma: A report from two centers in Western Japan. J Pediatr Surg, 50: 2102-2106, 2015.
  3. Yoneda A, Nishikawa M, Uehara S, Oue T, Usui N, Inoue M, Fukuzawa M, Okuyama H: Can neoadjuvant chemotherapy reduce the surgical risks for localized neuroblastoma patients with image-defined risk factors at the time of diagnosis? Pediatr Surg Int, 32: 209-214, 2016.
  4. Yoneda A, Nishikawa M, Uehara S, Oue T, Usui N, Inoue M, Fukuzawa M, Okuyama H: Can image-defined risk factors predict surgical complications in localized neuroblastoma? Eur J Pediatr Surg, 26: 117-122, 2016.
  5. Matthay KK, Maris JM, Schleiermacher G, Nakagawara A, Mackall CL, Diller L, Weiss WA: Neuroblasoma. Nat Rev Dis Primers, 2: 16078, 2016.
  6. Uryu K, Nishimura R, Kataoka K, Sato Y, Nakazawa A, Suzuki H, Yoshida K, Seki M, Hiwatari M, Isobe T, Shiraishi Y, Chiba K, Tanaka H, Miyano S, Koh K, Hanada R, Oka A, Hayashi Y, Ohira M, Kamijo T, Nagase H, Takimoto T, Tajiri T, Nakagawara A, Ogawa S, Takita J: Identification of the genetic and clinical characteristics of neuroblastomas using genome-wide analysis. Oncotarget, 8: 107513-107529, 2017.
  7. Hishiki T, Matsumoto K, Ohira M, Kamijo T, Shichino H, Kuroda T, Yoneda A, Soejima T, Nakazawa A, Takimoto T, Yokota I, Teramukai S, Takahashi H, Fukushima T, Kaneko T, Hara J, Kaneko M, Ikeda H, Tajiri T, Nakagawara A: Results of a phase II trial for high-risk neuroblastoma treatment protocol JN-H-07: a report from the Japan Childhood Cancer Group Neuroblastoma Committee (JNBSG). Int J Clin Oncol, doi: 10.1007/s10147-018-1281-8, 2018
  8. Nakagawara A, Li Y, Izumi H, Muramori K, Inada H, Nishi M: Neuroblastoma. Jpn J Clin Oncol, 48: 214-241, 2018.
  9. Iehara T, Yoneda A, Yokota I, Takahashi H, Teramukai S, Kamijyo T, Nakazawa A, Takimoto T, Kikuta A, Yagyu S, Ikeda H, Nakagawara A, Tajiri T: Results of a prospective clinical trial JN-L-10 using image-defined risk factors to inform surgical decisions for children with low-risk neuroblastoma disease: A report from the Japan Children’s Cancer Group Neuroblastoma Committee. Pediatr Blood Cancer, 66: e27914, 2019.
  10. Iehara T, Yoneda A, Kikuta A, Muraji T, Tokiwa K, Takahashi H, Teramukai S, Takimoto T, Yagyu S, Hosoi H, Tajiri T, JNBSG: A phase II JN-I-10 efficacy study of IDRF-based surgical decisions and stepwise treatment intensification for patients with intermediate-risk neuroblastoma: a study protocol. BMC Pediatr, 20: 212, 2020. doi: 10.1186/s12887-020-02061-5
  11. Kawano T, Souzaki R, Sumida W, Shimojima N, Hishiki T, Kinoshita Y, Uchida H, Tajiri T, Yoneda A, Oue T, Kuroda T, Hirobe S, Koshinaga T, Hiyama E, Nio M, Inomata Y, Taguchi T, Ieiri S: Current thoracoscopic approach for mediastinal neuroblastoma in Japan-results from nationwide multicenter survey. Pediatr Surg Int, 37: 1651-1658, 2021. doi: 10.1007/s00383-021-04998-9
  12. Ohira M, Nakamura Y, Takimoto T, Nakazawa A, Hishiki T, Matsumoto K, Shichino H, Iehara T, Nagase H, Fukushima T, Yoneda A, Tajiri T, Nakagawara A, Kamijo T: Retrospective Analysis of INRG Clinical and Genomic Factors for 605 Neuroblastomas in Japan: A Report from the Japan Children’s Cancer Group Neuroblastoma Committee (JCCG-JNBSG). Biomolecules, 12: 18, 2021. doi.org/10.3390/biom12010018
  13. Hara J, Nitani C, Shichino H, Kuroda T, Hishiki T, Soejima T, Mori T, Matsumoto K, Sasahara Y, Iehara T, Miyamura T, Kosaka Y, Takimoto T, Nakagawara A, Tajiri T, JNBSG: Outcome of children with relapsed high-risk neuroblastoma in Japan and analysis of the role of allogeneic hematopoietic stem cell transplantation. Jpn J Clin Oncol, 52: 486-492, 2022. doi: 10.1093/jjco/hyac007
  14. Nishimura N, Ishida T, Yokota I, Matsumoto K, Shichino H, Fujisaki H, Sarashina T, Kamijo T, Takimoto T, Iehara T, Tajiri T, JNBSG: Minimal residual disease detected by the 7NB-mRNAs ddPCR assay Is associated with disease progression in high-risk neuroblastoma patients: A prospective multicenter observational study in Japan. Biology (Basel), 12: 1350, 2023. doi: 10.3390/biology12101350
B）和文
  1. 田尻達郎，米田光宏，家原知子，常盤和明，連　利博，菊田　敦，菊地　陽，金川公夫，北村正幸，中川原章，中澤温子，高橋秀人，瀧本哲也，福島　敬，金子道夫，原　純一，池田　均，日本神経芽腫研究グループ（JNBSG）：【小児腫瘍における多施設共同臨床試験の背景と進捗】神経芽腫低・中間リスク群に対する臨床研究におけるIDRFの評価と外科治療ガイドライン．小児外科　43：1173-1178，2011．
  2. 家原知子，菊田　敦，菊地　陽，田尻達郎，米田光宏，常盤和明，連　利博，金川公夫，北村正幸，柳生茂希，中川原章，中澤温子，高橋秀人，瀧本哲也，福島　敬，金子道夫，原　純一，池田　均，日本神経芽腫研究グループ（JNBSG）：【小児腫瘍における多施設共同臨床試験の背景と進捗】神経芽腫低リスク群・中間リスク群．小児外科　43：1179-1183，2011．
  3. 七野浩之：【小児腫瘍における多施設共同臨床試験の背景と進捗】神経芽腫高リスク群に対するJNBSG臨床試験．小児外科　43：1184-1189，2011．
  4. 金子道夫：神経芽腫治療の進歩と今後の展望．日本小児血液・がん学会雑誌　49：3-10，2012．
  5. 瀧本哲也，池田　均：神経芽腫マススクリーニングのその後　日本小児がん学会と日本神経芽腫研究グループの登録データからみた本邦の神経芽腫実態把握の現況．日本小児血液・がん学会雑誌　49：304-309，2012．
  6. 田尻達郎：神経芽腫　神経芽腫の治療の現況と展望．日本小児血液・がん学会雑誌　49：366-372，2012．
  7. 中川原章：COG and JCCG　JCCGとCOG　小児血液・がん研究の将来へ向けたグローバルな挑戦．日本小児血液・がん学会雑誌　52：359-364，2016．
  8. 田尻達郎：【小児固形がんの最新のトピックス】神経芽腫のトピックス．小児外科　48：1185-1191，2016．

［Ⅲ］学会発表

A）国際学会・研究会
  1. Iehara T, Tsuchiya K, Yagyu S, et al: Is additional treatment necessary for a residual tumor in cases of intermediate-risk neuroblastoma? Advances in Neuroblastoma Research (ANR), 2014 May 13-16; Koln, Germany.
  2. Ohira M, Kamijo T, Nakamura Y, et al: Genome-based sub-classification of neuroblastoma: a retrospective study by using 573 neuroblastoma samples obtained in Japan. Advances in Neuroblastoma Research (ANR), 2014 May 13-16; Koln, Germany.
  3. Shichino H, Matsumoto K, Iehara T, et al: Feasibility of delayed local control treatment in patients with high risk neuroblastoma: report of a pilot study from the Japan Neuroblastoma Study Group (JNBSG). Advances in Neuroblastoma Research (ANR), 2014 May 13-16; Koln, Germany.
  4. Matsumoto K, Shichino H, Kuroda T, et al: MYCN amplification is not solely the prognostic factor in treating of high-risk neuroblastoma: A late phase II study of Japan Neuroblastoma Study Group (JNBSG). Advances in Neuroblastoma Research (ANR), 2014 May 13-16; Koln, Germany.
  5. Hishiki T, Kuroda T, Tajiri T, et al: Surgical treatment in patients enrolled in the nationwide phase II study NB-HR07 for advanced neuroblastoma: A report from Japan Neuroblastoma Study Group (JNBSG). Advances in Neuroblastoma Research (ANR), 2014 May 13-16; Koln, Germany.
  6. Yoneda A, Tajiri T, Iehara T, et al: Characteristcs of image defined risk factors (IDRFs) in patients enrolled the low risk protocol (JN-L-10) from the Japanese Neuroblastoma Study Group (JNBSG). 46th Congress of the International Society of Paediatric Oncology (SIOP), 2014 Oct 22-25; Toronto, Canada.
  7. Fumino S, Kimura K, Iehara T, et al: Validity and reliability of image-defined risk factors in localized neuroblastoma: A report from 2 territorial centers in Japan. 46th Congress of the International Society of Paediatric Oncology (SIOP), 2014 Oct 22-25; Toronto, Canada.
  8. Fumino S, Kimura K, Iehara T, et al: Validity of image-defined risk factors in localized neuroblastoma: A report from two centers in Western Japan. 48th Annual Meeting of the Pacific Association of Pediatric Surgeons, 2015 May 17-21; Jeju Island, South Korea.
  9. Matsumoto K, Ohira M, Kamijo T, et al: A: Molecular profiling including Genomic aberrations can reveal ultra high-risk group in the Japan Neuroblastoma Study Groups clinical trials for high-risk neuroblastoma. 47th Congress of the International Society of Paediatric Oncology (SIOP), 2015 Oct 8-11; Cape Town, South Africa.
  10. Yoneda A, Tajiri T, Iehara T, et al: Determination of timing of surgery based on IDRF: an observation study for low risk neuroblastomas (JN-L-10). 2015 Asia-Pacific Symposium of Neuroblastoma, 2015 Nov 14; Taipei, Taiwan.
  11. Hishiki T, Matsumoto K, Shichino H, et al: Analysis of the clinical outcome of high-risk neuroblastoma: Results from the late phase II study of Japan Neuroblastoma Study Group (JNBSG) JN-H-07. 2015 Asia-Pacific Symposium of Neuroblastoma, 2015 Nov 14; Taipei, Taiwan.
  12. Iehara T, Yagyu S, Ouchi K, et al: A new therapeutic strategy of neuroblastoma by Liquid biopsy. 2015 Asia-Pacific Symposium of Neuroblastoma, 2015 Nov 14; Taipei, Taiwan.
  13. Shichino H, Mugishima H, Iehara T, et al: Feasibility of delayed local control treatment in patient with high risk Neuroblastoma: Report of a pilot study from the Japan Neuroblastoma study group (JN-H-05). 2015 Asia-Pacific Symposium of Neuroblastoma, 2015 Nov 14; Taipei, Taiwan.
  14. Ohira M, Kamijo T, Takimoto T, et al: Genomic characterization of high-risk neuroblastoma in Japan: A retrospective study of 537 cases by using updated follow-up data based on INRG variables [Japan Neuroblastoma Study Group (JNBSG)]. Advances in Neuroblastoma Research (ANR), 2016 Jun 19-23; Queensland, Australia.
  15. Hishiki T, Yoneda A, Kuroda T, et al: Primary tumor resection after high dose chemotherapy with autologous hematopoietic stem cell transplantation is a safe and feasible option. A report from the Japanese neuroblastoma study group (JNBSG). Advances in Neuroblastoma Research (ANR), 2016 Jun 19-23; Queensland, Australia.
  16. Iehara T, Yoneda A, Takama Y, et al: Opsoclonus-myoclonus syndrome in neuroblastoma: A report from the Japan Neuroblastoma Study Group (JNBSG). Advances in Neuroblastoma Research (ANR), 2016 Jun 19-23; Queensland, Australia.
  17. Tajiri T: Progress of clinical study group for neuroblastoma in Japan -from JNBSG to JCCG neuroblastoma committee- [Key note lecture]. 24th Congress of the Asian Association of Pediatric Surgeons, 2016 May 24-26; Fukuoka, Japan.
  18. Yoneda A: Current Surgical Strategy for Neuroblastoma. 2016 SIOP Asia, 2016 May 27; Moscow, Russia.
  19. Matsumoto K, Yuza Y, Goto H, Ko K, Tomizawa D, Kaneko T: Survey on Pediatric Cancer Patients in Kanto-Koshinetsu Area after the Election of Childhood Cancer Core Hospitals in Japan. 2016 SIOP Asia, 2016 May 28; Moscow, Russia.
  20. Nakagawara K: Modern neuroblastoma treatment strategies in Asia. 2016 SIOP Asia, 2016 May 27; Moscow, Russia.
  21. Yoneda A, Tajiri T, Hishiki T: Delayed local treatment for high risk neuroblastoma – from the Japan neuroblastoma study group trial [Multidisciplinary team “IPSO-PROS-SIOP” symposium]. 48th Congress of the International Society of Paediatric Oncology (SIOP), 2016 Oct 19-22; Dublin, Ireland.
  22. Shichino H, Mugishima H, Matsumoto K, Hishiki T, Iehara T, Yoneda A, Soejima T, Takimoto T, Takahashi H, Teramukai S, Kamijo T, Nakazawa A, Fukushima T, Hosoi H, Tajiri T, Nakagawara A: A phase II study of bold delayed local control strategy in children with high risk neuroblastoma: Japan neuroblastoma study group (JN-H-11) trial. 48th Congress of the International Society of Paediatric Oncology (SIOP), 2016 Oct 19-22; Dublin, Ireland.
  23. Hishiki T, Yoneda A, Tajiri T: Local control for intermediate to high risk neuroblastoma – surgical oncologist’s view. 24th Asia Pacific Cancer Conference, 2017 Jun 24; Seoul, Korea.
  24. Iehara T, Matsumoto K, Shichino H, Yoneda A, Hishiki T, Kamijyo T, Soejima T, Nakazawa A, Takimoto T, Takahashi H, Teramukai S, Yagyu S, Fumino S, Hosoi H, Fukushima T, Hara J, Kaneko M, Ikeda H, Nakagawara A, Tajiri T, JNBSG: Treatment strategies for neuroblastoma patients in JCCG neuroblastoma committee (JNBSG). The 3rd Asia-Pacific International Symposium of Neuroblastoma (APSN), 2017 Oct 6; Tokyo, Japan.
  25. Yoneda A, Hishiki T, Ono S, Ise K, Uehara S, Souzaki R, Kazama T, Fuchimoto Y, Kitagawa Y, Fumino S, Takama Y, Kuroda T, Iehara T, Matsumoto K, Shichino H, Nakagawara A, Tajiri T, JNBSG: Surgical strategy in the JCCG neuroblastoma committee (JNBSG) clinical trials. The 3rd Asia-Pacific International Symposium of Neuroblastoma (APSN), 2017 Oct 6; Tokyo, Japan.
  26. Iehara T, Yokota I, Yoneda A, Kamijo T, Nakazawa A, Kikuta A, Takimoto T, Teramukai S, Hosoi H, Nakagawara A, Tajiri T: Interim results of a clinical trial of IDRF for intermediate-risk neuroblastoma from the Japan Neuroblastoma Study Group (JNBSG). 49th Congress of the International Society of Paediatric Oncology (SIOP), 2017 Oct 12-15; Washinton DC, USA.
  27. Iehara T, Yoneda A, Yokota I, Takahashi H, Teramukai S, Kamijyo T, Nakazawa A, Takimoto T, Kikuta A, Ikeda H, Nakagawara A, Tajiri T: Results of a prospective clinical trial JN-L-10 using IDRF-based surgical decision for children with low-risk neuroblastoma disease in Japan. Advances in Neuroblastoma Research (ANR), 2018 May 9-12; San Francisco, USA.
  28. Yoneda A, Iehara T, Yokota I, Takahashi H, Teramukai S, Kamijo T, Nakazawa A, Takimoto T, Kikuta A, Ikeda H, Nakagawara A, Tajiri T: Image-difined risk factors in patients enrolled in th low-riks protocol (JN-L-10) from the Japan Children’s Cancer Group Neuroblastoma Committee. Advances in Neuroblastoma Research (ANR), 2018 May 9-12; San Francisco, USA.
  29. Ohira M, Kamijo T, Sugino R, Haruta M, Takenobu H, Takimoto T, Nakazawa A, Hishiki T, Matsumoto K, Shichino H, Ushijima T, Iehara T, Nakamura Y, Nagase H, Takita J, Yoneda A, Fukushima T, Tajiri T, Nakagawara A: Genomic characterization of high-risk/ultra-high-risk neuroblastomas found in 610 patients registered in Japan Children’s Cancer Group (JCCG) Neuroblastoma Committee (JNBSG). Advances in Neuroblastoma Research (ANR), 2018 May 9-12; San Francisco, USA.
  30. Tajiri T: Current Surgical Strategy of Neuroblastoma [Workshop on current management strategies and emerging treatmentsi in pediatric surgery]. 32nd International Symposium on Paediatric Surgical Research (ISPSR), 2019 Sep 6; Fukuoka, Japan.
  31. Yoneda A, Iehara T, Yokota I, Takahashi H, Teramukai S, Kamijo T, Nakazawa A, Takimoto T , Kikuta A, Ikeda H, Nakagawara A, Tajiri T, JNBSG: The evaluation of the new guideline for assessing image-difined risk factors in the low-risk protocol (JN-L-10) from the Japan Children’s Cancer Group Neuroblastoma Committee. 51st Congress of the International Society of Paediatric Oncology (SIOP), 2019 Oct 23-26; Lyon, France.
  32. Hishiki T, Yamada Y, Kawakubo N, Yoneda A, Tajiri T: Surgical management of neuroblastoma—institutional experience and the nationwide clinical trials in Japan [Pediatric: Symposium—Pediatric Surgical Oncology]. Annual Congress of the Korean Surgical Society (ACKSS), 2019 Oct 31-Nov 2; Seoul, Korea.
  33. Yoneda A, Iehara T, Yokota I, Takahashi H, Teramukai S, Kamijo T, Nakazawa A, Takimoto T, Kikuta A, Ikeda H, Nakagawara A, Tajiri T: The evaluation of the treatment results according to the relationship of the renal vessels and tumor in low-risk patients with abdominal neuroblastoma -an analysis of the patients who enrolled in the low-risk protocol (JN-L-10) from the Japna Children’s Cancer Group Neuroblastoma Committee. 52nd Congress of the International Society of Paediatric Oncology (SIOP), 2020 Oct 14-17; Web.
  34. Ohira M, Shichino H, Kubo T, Haruta M, Takimoto T, Nakazawa A, Yamazaki F, Matsumoto K, Nagase H, Tajiri T, Nakagawara A, Ichikawa H, Hishiki T, Kamijo T, JCCG-JNBSG: Genomic characterization of high-risk neuroblastoma by cancer gene panel tests. Advances in Neuroblastoma Research (ANR), 2021 Jan 25-27; web (only abstract).
  35. Yoneda A, Iehara T, Yokota I, Takahashi H, Teramukai S, Kamijo T, Nakazawa A, Takimoto T, Kikuta A, Ikeda H, Nakagawara A, Tajiri T: The evaluation of the treatment results according to the relationship of the renal vessels and tumor in low-risk patients with abdominal neuroblastoma -an analysis of the patients who enrolled in low-risk protocol (JN-L-10) from the Japna Children’s. Advances in Neuroblastoma Research (ANR), 2021 Jan 25-27; web (only abstract).
  36. Matsumoto K, Shichino H, Yoneda A, Hishiki T, Hara J, Iehara T, Soejima T, Nozawa K, Okita H, Takimoto T, Yokota I, Teramukai S, Kamijo T, Watanabe K, Hino M, Fukushima T, Hiyama E, Nakagawara A, Tajiri T: Delayed local treatment and Busulfan/Melphalan as a myeloablative chemotherapy for high-risk neuroblastoma (JN-H-15): a report from Neuroblastoma Committee of Japan Children’s Cancer Group (JCCG) Trial. Advances in Neuroblastoma Research (ANR), 2021 Jan 25-27; web (only abstract).
  37. Shichino H, Matsumoto K, Hishiki T, Iehara T, Yoneda A, Soejima T, Takimoto,T, Takahashi H, Yokota I, Teramukai S, Kamijo T, Nakazawa A, Fukushima T, Hosoi H, Mugishima H, Nakagawara A, Tajiri T: A nationwide phase II study of extremely delayed local control strategy in children with high risk neuroblastoma: Japan Children’s Cancer Group – Neuroblastoma Committee Trial (JN-H-11). Advances in Neuroblastoma Research (ANR), 2021 Jan 25-27; web (only abstract).
  38. Yoneda A, Iehara T, Kikuta A, Muraji T, Tokiwa K, Takahashi H, Teramukai S, Takimoto T, Yagyu S, Hosoi H, Tajiri T: Surgical evaluation in the intermediate-risk neuroblastoma protocol JN-I-10 from the Japan Children’s Cancer Group Neuroblastoma Committee. 53rd Congress of the International Society of Paediatric Oncology (SIOP), 2022 Sep 28 – Oct 1; Barcelona.
  39. Yoneda A, Shichino H, Hishiki T, Matsumoto K, Ohira M, Kamijo T, Kuroda T, Soejima T, Nakazawa A, Takimoto T, Yokota I, Teramukai S, Takahashi H, Fukushima T, Hara J, Kaneko M, Ikeda H, Tajiri T, Mugishima H, Nakagawara A: Surgical outcome of a nationwide phase II study of delayed local treatment for children with high-risk neuroblastoma (JN-H-11). Advances in Neuroblastoma Research (ANR), 2023 May 15-18; Amsterdam, the Netherlands.
  40. Matsumoto K, Nozawa K, Shichino H, Yoneda A, Soejima T, Okita H, Takimoto T, Yokota I, Kamijo T, Nakagawara A, Tajiri T, JCCG-NB: A postinduction Curie Score of more than 2 in patients with MYCN-nonamplified tumor treated by JN-H-15 was not associated with poor prognosis. Advances in Neuroblastoma Research (ANR), 2023 May 15-18; Amsterdam, the Netherlands.
  41. Ohira M, Nakamura Y, Takimoto T, Nakazawa A, Hishiki T, Matsumoto K, Shichino H, Iehara T, Fukushima T, Yoneda A, Tajiri T, Nakagawara A, Kamijo T, JCCG-NB: Retrospective analysis of INRG clinical and genomic markers for 605 neuroblastomas in Japan: A report from JCCG-JNBSG. Advances in Neuroblastoma Research (ANR), 2023 May 15-18; Amsterdam, the Netherlands.
  42. Ohira M, Haruta M, Sugawara M, Shichino H, Hishiki T, Yoneda A, Matsumoto K, Takimoto T, Nakazawa A, Okita H, Higashimoto H, Ushijima T, Nagase H, Ichikawa H, Tajiri T, Nakagawara A, Kamijo T, JCCG-JNBSG: Genome analysis of 95 cases registered in JCCG-JNBSG JN-H-11 and JN-H-07 clinical studies for high-risk neuroblastoma. Advances in Neuroblastoma Research (ANR), 2023 May 15-18; Amsterdam, the Netherlands.
  43. Nishimura N, Ishida T, Yokota I, Matsumoto K, Shichino H, Fujisaki H, Sarashina T, Kamijo T, Takimoto T, Iehara T, Tajiri T: Prospective multicenter observational study of minimal residual disease detected by 7NB-mRNAs ddPCR assay in high-risk neuroblastoma patients. Advances in Neuroblastoma Research (ANR), 2023 May 15-18; Amsterdam, the Netherlands.
  44. Matsumoto K: Japanese trials for high-risk neuroblastoma – 15 years experience. 2nd Annual Meeting of Asian Pediatric Hematology and Oncology Group (APHOG), 2023 May 21; Yerevan, Armenia.
  45. Yoneda A, Iehara T, Kikuta A, Muraji T, Tokiwa K, Takahashi H, Teramukai S, Takimoto T, Yagyu S, Hosoi H, Tajiri T: Surgical outcome according to the relationship between the renal vessels and tumor in the low- and the intermediate-risk patients with abdominal neuroblastoma. 55th Congress of the International Society of Paediatric Oncology (SIOP), Oct 11–14; Ottawa, Canada.
B）国内学会・研究会
  1. 田尻達郎，中川原章：JNBSGの現況と今後の展開【シンポジウム；小児悪性固形腫瘍の臨床研究 グループの現状と今後】．第51回日本小児外科学会学術集会　2014年5月9日；大阪．
  2. 田尻達郎：神経芽腫に対する外科療法【シンポジウム】．第56回日本小児血液・がん学会学術集会　2014年11月30日；岡山．
  3. 田尻達郎：小児固形がん臨床研究グループの現状と展望「日本神経芽腫研究グループ（JNBSG）の現状と将来について」【教育講演】．京都府小児がん拠点病院公開講座　2015年1月31日；京都．
  4. 田尻達郎：本邦における神経芽腫治療の現状と今後【特別講演】．第21回愛媛小児血液・悪性腫瘍研究会　2015年6月26日；愛媛．
  5. 田尻達郎：本邦における神経芽腫の治療—小児外科医の役割—【特別講演】．第35回山口県小児外科研究会　2015年9月10日；山口．
  6. 田尻達郎：神経芽腫の多施設臨床試験とトランスレーショナルリサーチ．神戸大学医学部大学院特別講義　2015年11月20日；兵庫．
  7. 田尻達郎：本邦神経芽腫治療現状今後【特別講演】．第11回大分血液・腫瘍セミナー　2016年3月10日；大分．
  8. 田尻達郎：神経芽腫マススクリーニング休止後の再評価【シンポジウム小児の臨床現場からみた現在の保健・医療制度の問題点】．第12回日本小児医療政策研究会　2016年3月19日；東京．
  9. 米田光宏：神経芽腫における外科療法の標準化．第53回日本小児外科学会学術集会　2016年5月25日；福岡．
  10. 田尻達郎：神経芽腫の治療の現状と将来【特別講演】．第27回群馬小児がん研究会　2016年8月26日；群馬．
  11. 大平美紀，上條岳彦，瀧本哲也，中澤温子，松本公一，七野浩之，菱木知郎，家原知子，中村洋子，永瀬浩喜，米田光宏，福島　敬，田尻達郎，中川原章：国際リスク分類システムと連携した神経芽腫分子生物学的データベースの構築と高リスク神経芽腫のゲノム解析．第58回日本小児血液・がん学会学術集会　2016年12月15日；東京．
  12. 上原秀一郎，菱木知郎，宗崎良太，風間理郎，伊勢一哉，渕本康史，北河徳彦，小野　滋，田尻達郎，黒田達夫，米田光宏：JCCG神経芽腫委員会外科療法委員会の取り組みと最近のプロトコール治療による外科治療について【パネルディスカッションJCCGの外科療法委員会の取り組み】．第54回日本小児外科学会学術集会　2017年5月13日；仙台．
  13. 大平美紀，上條岳彦，瀧本哲也，中澤温子，松本公一，菱木知郎，牛島俊和，中村洋子，巽　康年，永瀬浩喜，田尻達郎，中川原章，JCCG JNBSG：ゲノム・エピゲノム異常を用いた神経芽腫の新規リスク分類—JCCG神経芽腫委員会（JNBSG）高リスク臨床試験登録例の解析．第76回日本癌学会学術総会　2017年9月29日；横浜．
  14. 上原秀一郎，菱木知郎，宗崎良太，高間勇一，文野誠久，風間理郎，伊勢一哉，淵本康史，北河徳彦，小野　滋，田尻達郎，黒田達夫，米田光宏：JCCG神経芽腫委員会外科療法委員会の活動と最近のプロトコール治療による外科治療について【シンポジウム臨床試験から視た小児手術】．第79回日本臨床外科学会総会　2017年11月23日；東京．
  15. 上原秀一郎，米田光宏，菱木知郎，三藤賢志，家原知子，松本公一，七野浩之，田尻達郎，福澤正洋，奥山宏臣：QOLを重視した神経芽腫における外科治療の現状と今後—各リスク群に応じた戦略【シンポジウムQOLを重視した小児がんにおける局所治療（外科療法と放射線療法）の現状と今後】．第55回日本小児外科学会学術集会，2018年5月31日；新潟．
  16. Ohira M, Sugino R, Haruta M, Takenobu H, Takimoto T, Hishiki T, Matsumoto K, Nakazawa A, Shichino H, Ushijima T, Nakamura Y, Nagase H, Iehara T, Teramukai S, Tajiri T, Aburatani H, Nakagawara A, Kamijo T, JNBSG: Genomic characterization of ultra-high-risk neuroblastoma. 第77回日本癌学会学術総会，2018年9月27〜29日；大阪．
  17. 菱木知郎：Results of a phase II trial for high-risk neuroblastoma treatment protocol JN-H-07: A report from the Japan Childhood Cancer Group Neuroblastoma Committee (JNBSG). 第119回日本外科学会定期学術集会，2019年4月19日；大阪．
  18. Ohira M, Shichino H, Kubo T, Haruta M, Takimoto T, Nakazawa A, Nagase H, Tajiri T, Nakagawara A, Ichikawa H, Hishiki T, Kamijo T, JNBSG: Genomic characterization of high-risk neuroblastoma by cancer panels. 第78回日本癌学会学術総会，2019年9月26〜28日；京都．
  19. Iehara T, Matsumoto K, Shichino H, Yoneda A, Hishiki T, Kamijyo T, Soejima T, Nakazawa A, Takimoto T, Teramukai S, Yokota I, Fukushima T, Fumino S, Tajiri T, JNBSG: Treatment strategies for neuroblastoma patients in JCCG neuroblastoma committee (JNBSG)【日韓合同ジョイントセッション神経芽腫】. 第61回日本小児血液・がん学会学術集会，2019年11月16日；広島．
  20. Yoneda A, Hishiki T, Tajiri T, Iehara T, Matsumoto K, Shichino H, Nagawara A, JNBSG: Surgical strategy in the JCCG neuroblastoma committee (JNBSG) clinical trials【日韓合同ジョイントセッション神経芽腫】. 第61回日本小児血液・がん学会学術集会，2019年11月16日；広島．
  21. Ohira M, Shichino H, Kubo T, Haruta M, Takimoto T, Nakazawa A, Yamazaki F, Nagase H, Tajiri T, Nakagawara A, Ichikawa H, Hishiki T, Kamijo T, JNBSG: Toward genome medicine for pediatric cancer: Genomic characterization of high-risk neuroblastoma by cancer gene panel tests. 第61回日本小児血液・がん学会学術集会，2019年11月14日；広島．
  22. 大平美紀，七野浩之，久保　崇，春田雅之，瀧本哲也，中澤温子，山崎文登，松本公一，永瀬浩喜，田尻達郎，中川原章，市川　仁，菱木知郎，上條岳彦，JNBSG：高リスク神経芽腫の小児がん用NCCオンコパネル解析．第79回日本癌学会学術総会，2020年10月1〜3日；広島（webオンデマンド）．
  23. 大平美紀，七野浩之，久保　崇，春田雅之，瀧本哲也，中澤温子，山崎文登，松本公一，永瀬浩喜，田尻達郎，中川原章，市川　仁，菱木知郎，上條岳彦，JNBSG：【優秀演題】高リスク神経芽腫の小児がん用NCCオンコパネル解析．第62回日本小児血液・がん学会学術集会，2020 年11月20〜22日；福島（webオンデマンド）．
  24. 宗崎良太，菱木知郎，米田光宏，小野　滋，伊勢一哉，上原秀一郎，風間理郎，渕本康史，北河徳彦，文野誠久，高間勇一，横井暁子，中田光政，黒田達夫，田尻達郎，JNBSG外科療法委員会：神経芽腫の外科療法について〜切除度の評価について〜【ワークショップ　固形腫瘍の切除度評価はいつ・誰が・どのように行うべきか?】．第62回日本小児血液・がん学会学術集会，2020 年11月20〜22日；福島（webオンデマンド）．
  25. 米田光宏，家原知子，菱木知郎，横田　勲，高橋秀人，手良向聡，上條岳彦，中澤温子，瀧本哲也，菊田　敦，柳生茂希，池田　均，中川原章，田尻達郎：神経芽腫低リスクプロトコール（JN-L-10）におけるIDRFの検討【要望演題　小児がんの新規診断技術・治療，臨床試験】．第58回日本小児外科学会学術集会，2021年4月28日；横浜．
  26. 大平美紀，春田雅之，菅原大樹，七野浩之，菱木知郎，瀧本哲也，中澤温子，大喜多肇，東本浩子，牛島俊和，永瀬浩喜，市川　仁，田尻達郎，中川原章，上條岳彦：高リスク神経芽腫臨床試験例における各種ゲノムマーカーの後方視的解析．第80回日本癌学会学術集会，2021年10月2日；横浜．
  27. Ohira M, Haruta M, Sugawara M, Shichino H, Hishiki T, Takimoto T, Nakazawa A, Okita H, Tajiri T, Kamijo T, JNBSG: Genome analysis of 95 cases registered in JCCG-JNBSG JN-H-11 and JN-H-07 clinical studies for high-risk neuroblastoma. 第63回日本小児血液・がん学会学術集会，2021年11月25〜27日；Web．
  28. Sugawara M, Haruta M, Nakazawa A, Okita H, Takimoto T, Tajiri T, Uehara S, Koshinaga T, Ohira M, Kamijo T: Abnormalities of telomere maintenance mechanism in neuroblastoma group tumors. 第63回日本小児血液・がん学会学術集会，2021年11月25〜27日；Web．
  29. Ohira M, Nakamura Y, Takimoto T, Nakazawa A, Hishiki T, Matsumoto K, Shichino H, Iehara T, Nagase H, Fukushima T, Yoneda A, Tajiri T, Nakagawara A, Kamijo T: Retrospective analysis of INRG clinical and genomic factors for 605 neuroblastomas in Japa. 第81回日本癌学会学術総会，2022年9月29日〜10月1日；横浜．
  30. Matsumoto K, Shichino H, Yoneda A, Soejima T, Nozawa K, Okita H, Takimoto T, Yokota I, Kamijo T, Tajiri T: Delayed local treatment and Busulfan/Melphalan as a myeloablative chemotherapy for high-risk neuroblasoma (JN-H-15). 第64回日本小児血液・がん学会学術集会，2022年11月25〜27日；東京．
  31. Ohira M, Takimoto T, Nakazawa A, Hishiki T, Matsumoto K, Shichino H, Iehara T, Tajiri T, Nakagawara A, Kamijo T: Retrospective analysis of INRG markers for 605 neuroblastomas in Japan: A report from JCCG-JNBSG. 第64回日本小児血液・がん学会学術集会，2022年11月25〜27日；東京．
  32. Ohira M, Haruta M, Takimoto T, Nakazawa A, Nakamura Y, Takatori A, Iehara T, Tajiri T, Nakagawara A, Kamijo T: Genome copy number analysis of relapsed neuroblastoma. 第82回日本癌学会学術総会，2023年9月21〜23日；横浜．
  33. Ohira M, Haruta M, Takimoto T, Nakazawa A, Nakamura Y, Takatori A, Iehara T, Tajiri T, Nakagawara A, Kamijo T: Genome copy number analyses of primary and delayed primary or relapsed/refractory neuroblastoma sample pairs resected from the 66 JCCG-JNBSG registered cases. 第65回日本小児血液・がん学会学術集会，2023年9月29〜10月1日；札幌．
  34. Nishimura N, Ishida T, Yokota I, Matsumoto K, Shichino H, Kamijo T, Takimoto T, Iehara T, Tajiri T: Prospective multicenter observational study aimed at validating a prognostic value of minimal residual disease in high-risk neuroblastoma patients. 第65回日本小児血液・がん学会学術集会，2023年9月29〜10月1日；札幌．